Antibody-drug conjugates (ADCs) have advantages including target specificity, wide therapeutic index and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (∼150 kDa), which markedly slows ...
May 16, 2023
0
12
Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there's a critical need for new treatment options, especially for advanced cancers that grow back after standard ...
Apr 17, 2023
0
45
Scientists from the University of California, Irvine, the University of Michigan and the University of Texas MD Anderson Cancer Center have made a significant contribution to the field of pancreatic cancer research. Their ...
Apr 13, 2023
0
25
US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.
Mar 13, 2023
0
2
Patients with serious pneumococcal infections, including pneumonia and sepsis, are at a substantially increased risk of heart attack after the onset of infection according to a Vanderbilt study published in Clinical Infectious ...
Mar 2, 2023
0
20
Building a new precision cancer treatment comes with no shortage of scientific challenges. Now, a group of University of Florida researchers have made a significant discovery in the effort to develop potent, highly targeted ...
Feb 20, 2023
0
68
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic ...
Feb 13, 2023
0
38
Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), is investigating which patients with metastatic bladder cancer ...
Dec 30, 2022
0
17
The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine therapy as first-line therapy for patients with metastatic, estrogen receptor (ER)-positive/HER2-negative breast cancer ...
Dec 8, 2022
0
2
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole ...
Dec 7, 2022
0
2
